Market News & Trends
Bellerophon Announces FDA Agreement on Phase 2b Study Design
Bellerophon Therapeutics, Inc. recently announced agreement with the US FDA on the Phase 2 study design for INOpulse in pulmonary hypertension associated with Interstitial Lung…
Biological Bypass Shows Promise in Coronary Artery Disease
A new gene therapy that targets the heart and requires only one treatment session has been found safe for patients with coronary artery disease, according…
UPM Pharmaceuticals Successfully Serializes Its First Pharmaceutical Product
UPM Pharmaceuticals successfully serialized their first product in May of this year. UPM anticipates having all of their clients' products serialized by November 2017. In…
Inotek Announces Top-Line Results of Phase II Fixed-Dose Combination Trial, Explores Strategic Alternatives
Inotek Pharmaceuticals Corporation recently announced top-line results of the Phase 2 fixed-dose combination (FDC) trial of trabodenoson and latanoprost for the treatment of glaucoma. The…
Nektar Therapeutcs Presents New Preclinical Data for First-In-Class Regulatory T Cell Stimulator
Nektar Therapeutics recently announced positive preclinical results for NKTR-358, a first-in-class resolution therapeutic for autoimmune disease. The new preclinical data demonstrate that treatment with NKTR-358…
Oncology Venture & Eisai Forge Exclusive Global License Agreement
Oncology Venture AB and 2X Oncology, Inc. recently announced that Oncology Venture has entered into an exclusive global license agreement with Eisai Inc. for Eisai’s…
Pfizer Partners With Catalent for Exclusive Long-Term Supply Agreement
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, recently announced that…
Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration
Daiichi Sankyo Co., Limited (hereafter, Daiichi Sankyo), Max Planck Innovation GmbH and the Lead Discovery Center GmbH have signed an agreement providing Daiichi Sankyo with…
Conatus Announces Receipt of $7-Million Payment From Novartis
Conatus Pharmaceuticals Inc. recently announced that its exclusive license with Novartis for the global development and commercialization of emricasan has become effective under terms of…
BioTelemetry Reaches a Final Milestone in Acquisition of LifeWatch AG
BioTelemetry, Inc., the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care,…
Edge Therapeutics Announces Commercial Supply Agreement With Oakwood Laboratories
Edge Therapeutics, Inc. recently announced it has entered into a supply agreement and an amended and restated development agreement with Oakwood Laboratories for the…
Inovio’s DNA-Based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation
Inovio Pharmaceuticals, Inc. recently announced its DNA-based monoclonal antibody product for flu produced broadly cross-reactive antibodies that provided complete protection from a lethal challenge with…
Financial Milestone Achieved in Catalyst’s Subcutaneous Factor IX Program
Catalyst Biosciences, Inc. recently announced it has achieved a financial milestone under its collaboration with ISU Abxis. In June 2017, the first patient and cohort…
Heart Failure Market to Surpass $16 billion by 2026
The heart failure space across the seven key markets of the US, France, Germany, Italy, Spain, the UK, and Japan is set to grow from…
Prothena Announces Initiation of Phase 2 Study, Triggers Milestone
Prothena Corporation plc recently announced that the first patient has been enrolled in PASADENA, a global Phase 2 study of PRX002/RG7935 in patients with early…
Onxeo Announces Positive Preclinical Results
Onxeo S.A. recently announced positive preclinical proof-of-concept results confirming the activity via systemic (intravenous, IV) administration of AsiDNA, the company’s first-in-class DNA repair inhibitor. A…
M Pharmaceutical In-Licenses Novel Pediatric Orphan Drug
M Pharmaceutical Inc. recently announced that it has in-licensed a novel drug product that should qualify as an Orphan Drug under the US Orphan Drug…
Galapagos NV Announces New Phase 2 Study
“We are pleased with the initiation of this new Phase 2 study with filgotinib," said Dr. Walid Abi-Saab, Chief Medical Officer of Galapagos. "We look…
Cytokinetics Announces Baseline Data From First Cohort of Phase 2 Clinical Trial
Cytokinetics, Inc. recently announced that data relating to patient baseline characteristics and the reasons for patient screen failure, both from the first cohort of the…
ProQR’s Drug Candidate Receives Orphan Drug Designation
ProQR Therapeutics N.V. recently announced its investigational drug QRX-411 has received orphan drug designation (ODD) from the US FDA and EMA for the treatment of…
